Actinium Pharmaceuticals, Inc.
AMEX:ATNMBiotechnology
+$0.22 today
- Market cap
- $51.56M
- Beta
- 0.02
- P/E (TTM)
- 4.4
- EPS (TTM)
- $0.36
Volume 0.18M
Average 0.15M
ATNM Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Actinium Pharmaceuticals, Inc.AMEX: ATNM
Selling, General & Admin · Q2 FY2026 · quarter ended Jun 2026
Selling, general & admin declines year over year
Q2 FY2026 selling, general & admin of $2.06M fell 21.6% year over year, ahead of the -56.6% change in trailing-twelve-month selling, general & admin. Sequentially, it rose 20.9% from the prior quarter. Over 3 fiscal years it compounded at +8.2% a year.
Context
- Selling, general & admin amounted to 16903.3% of revenue in FY2025.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 2 analysts of $2.47B (+16157.6%) for the fiscal year ending Dec 2026, a step up from the +26.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $2.06M+20.9% QoQ
- Last fiscal yearDec 2025
- $15.21M+26.0% YoY
- LTMJun 2026
- $7.41M-56.6% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 15.21M USD
- Year-over-year change
- +26.0%
- 4-year CAGR
- +17.1%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 15.21M | +26.0% |
| FY2024 | 2024-12-31 | 12.08M | -9.4% |
| FY2023 | 2023-12-31 | 13.33M | +11.1% |
| FY2022 | 2022-12-31 | 12M | +48.6% |
| FY2021 | 2021-12-31 | 8.08M | — |
Selling, General & Admin vs competitors
How ATNM compares with its peers on the latest reported figures
- ATNM's LTM Jun 2026 selling, general & admin of $7.41M is the lowest of the 5 companies compared; the peer median is $661.4M.
- Its year-over-year change of -56.6% is the lowest of 5, against a peer median of +9682.9%.
- Selling, general & admin amounts to 21.1% of revenue for ATNM, versus a peer median of 51.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $3.07B | +22461.6% | +0.7% | — | |
| LTM Mar 2026 | $1.3B | +19278.2% | -20.7% | — | |
| LTM Mar 2026 | $27.78M | +2.3% | -0.3% | 51.9% | |
OKUROnKure Therapeutics, Inc. | LTM Mar 2026 | $14.61M | +87.7% | +55.5% | — |
| LTM Jun 2026 | $7.41M | -56.6% | +8.2% | 21.1% | |
| Peer median (excluding ATNM) | $661.4M | +9682.9% | +0.2% | 51.9% | |
Competitors are the stored peer set for ATNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.14M | 1.03M | 81K | 0 | 90K |
| Cost of Revenue | 524K | 0 | 0 | 811K | 0 |
| Gross Profit | 620K | 1.03M | 81K | (811K) | 90K |
| Gross Margin | 54.2% | 100.0% | 100.0% | — | 100.0% |
| Research & Development | 17.51M | 23.14M | 38.67M | 30.05M | 21.12M |
| Selling, General & Admin | 8.08M | 12M | 13.33M | 12.08M | 15.21M |
| Operating Expenses | 25.58M | 35.13M | 52M | 41.31M | 36.34M |
| Depreciation & Amortization | 524K | 699K | 790K | 811K | 821K |
| EBITDA | (24.25M) | (32.32M) | (48.03M) | (37.43M) | (33.07M) |
| EBITDA Margin | -2119.8% | -3137.7% | -59293.8% | — | -36740.0% |
| Operating Income | (24.96M) | (34.1M) | (51.92M) | (42.12M) | (36.25M) |
| Operating Margin | -2182.2% | -3311.1% | -64098.8% | — | -40274.4% |
| Interest Income | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 190K | 1.09M | 3.1M | 3.88M | 2.36M |
| Income Before Tax | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Pre-Tax Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.77M) | (33.02M) | (48.82M) | (38.24M) | (33.89M) |
| Net Margin | -2165.6% | -3205.5% | -60269.1% | — | -37652.2% |
| EPS (Basic) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| EPS (Diluted) | (1.20) | (1.37) | (1.83) | (1.27) | (1.09) |
| Weighted Avg Shares | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
| Weighted Avg Shares (Diluted) | 20.57M | 24.14M | 26.6M | 30.07M | 31.2M |
Actinium Pharmaceuticals, Inc.
AMEX:ATNM
Intrinsic Alpha fair value
Locked
Current Price
$1.64
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.